Change in TNF-a, IL-6, CRP, BAP test, IGF-1, from baseline to T21 in the Ma-Pi 2 group versus control group
| Median (1°–3° quartile) [95% CI] | Ma-Pi 2 (n=25) | Control (n=26) | p Value |
|---|---|---|---|
| TNF-α (pg/mL)* | −18 (−33 to 0) | −20 (−40 to −5) | 0.623 |
| [−28.1 to −8.1] | [−27.9 to −4.9] | ||
| IL-6 (pg/mL)* | 0.4 (−1.5 to 2.9) | 0.3 (−3 to 3) | 0.888 |
| [−1 to 1.8] | [−1.5 to 2.2] | ||
| CRP (%)† | −33.1 (−68.8 to 0) | −23.1 (−65.5 to 2) | 0.211 |
| [−54.9 to −11.4] | [−45 to −1.2] | ||
| BAP test (%)† | 26.9 (9.9 to 63.8) | 17.9 (−2.1 to 61.3) | 0.523 |
| [9.1 to 44.7] | [−3.3 to 39.1] | ||
| IGF-1 (%)† | −12.6 (−38.3 to −2) | 22.7 (0.5 to 114.6) | <0.001 |
| [−24 to −1.1] | [−14.1 to 59.5] |
Changes from baseline to T21 are statistically significant when the 95% CIs do not include zero.
p Value by Wilcoxon rank-sum test are referred to differences between the two treatment groups.
Variables were expressed as:
*Absolute difference
†Percent change.
BAP test, biological antioxidant potential of plasma test; CRP, C reactive protein; IGF-1, insulin-like growth factor-1; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.